Notably, immune checkpoint inhibitors targeting PD-1/PD-L1 have demonstrated some efficacy in ESCC, yet only a subset of patients respond favorably (7, 8), highlighting the need for additional immune-related biomarkers to guide precision medicine. Here, CD274 is linked to esophageal squamous cell carcinoma.